logo

For the Inventor, By the Inventor

Seattle, WA, United States of America

Dendreon Corporation


USPTO Granted Patents = 53

% Expired Patents = 43.4



Trademarks = 4

Forward Citations = 505

Loading Chart...
Loading Chart...

92 inventors (with patents filed for the assignee):

goldMedal Reiner Laus (16 out of 17 patents)

silverMedal Edwin L Madison (7 out of 36 patents)

bronzeMedal Ofir Moreno (7 out of 17 patents)

4.  David Duncan (7 out of 10 patents)

5.  Lori A Jones (7 out of 8 patents)

6.  Odile Esther Levy (7 out of 29 patents)

7.  Thomas Graddis (6 out of 8 patents)

8.  Damir Vidovic (6 out of 6 patents)

9.  Sateesh Kumar Natarajan (6 out of 8 patents)

10.  Ashok Arasappan (5 out of 49 patents)

11.  Curtis L Ruegg (5 out of 19 patents)

12.  Stephane L Bogen (5 out of 49 patents)

13.  Edgar Ong (5 out of 20 patents)

14.  Tin-Yau Chan (5 out of 25 patents)

15.  F George Njoroge (5 out of 99 patents)


Core Competencies:
Cancer Antigens
Immunotherapy
NK Cell Activity
HER-2/Neu Epitopes
Serine Protease Inhibitors
Dendritic Cells
Major Histocompatibility Complex
Antigen Presentation
Polypeptides
Antibodies
Tumor Antigens
Immunostimulatory Compositions

53 patents:

1. 10261091 - Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome (2019-04-16),
2. 9051385 - Compositions employing alternative reading frame polypeptides for the treatment of cancer and infectious disease (2015-06-09),
3. 8658177 - Promiscuous HER-2/Neu CD4 T cell epitopes (2014-02-25),
4. 8647865 - Promiscuous PAP CD4 T cell epitopes (2014-02-11),
5. 8618155 - Small-molecule modulators of Trp-p8 activity (2013-12-31),
6. 8614243 - Small-molecule modulators of Trp-p8 activity (2013-12-24),
7. 8540982 - Methods for inducing a natural killer (NK) cell-mediated immune response and for increasing NK cell activity (2013-09-24),
8. 8389730 - Compositions and methods for the treatment of disease associated with TRP-P8 expression (2013-03-05),
9. 8362264 - Compositions and methods for the treatment of disease associated with Trp-p8 expression (2013-01-29),
10. 8361479 - Promiscuous PAP CD4 T cell epitopes (2013-01-29),
11. 8354507 - HLA-DR specific antibodies, compositions and methods (2013-01-15),
12. 8263757 - Promiscuous HER-2/Neu CD4 T cell epitopes (2012-09-11),
13. 8153120 - Methods for inducing a natural killer (NK) cell-mediated immune response and for increasing NK cell activity (2012-04-10),
14. RE43298 - Peptides as NS3-serine protease inhibitors of hepatitis C virus (2012-04-02),
15. 7972602 - Promiscuous HER-2/Neu CD4 T cell epitopes (2011-07-05),
Dendreon Corporation, based in Seattle, WA, specializes in cancer immunotherapy, focusing on innovative treatments that harness the body's immune system to combat cancer. The company is known for its work with cancer antigens and the development of therapies that enhance NK cell activity and utilize dendritic cells for effective antigen presentation. Dendreon's research encompasses critical areas such as HER-2/Neu epitopes and serine protease inhibitors, positioning it as a leader in advancing therapeutic options for cancer patients.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Dendreon Corporation
53 Patents

#51 in Seattle, WA

#148 in Washington

#6,661 in US

#13,309 in the World

Seattle, WA (US)
Seattle, WA, United States of America

Dendreon Corporation

Forward Citations = 505

92 inventors:

goldMedal Reiner Laus (16 out of 17 patents)

silverMedal Edwin L Madison (7 out of 36 patents)

bronzeMedal Ofir Moreno (7 out of 17 patents)

4.  David Duncan (7 out of 10 patents)

5.  Lori A Jones (7 out of 8 patents)

Please report any incorrect information to [email protected]
Loading…